Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating restated by research analysts at TheStreet in a report released on Tuesday, AnalystRatings.Net reports. The analysts wrote, “Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a hold with a ratings score of C+. The company’s strengths can be seen in multiple areas, such as its […]
TheStreet Reiterates Hold Rating for Regeneron Pharmaceuticals (REGN) is a post from: Zolmax
The post TheStreet Reiterates Hold Rating for Regeneron Pharmaceuticals (REGN) appeared first on Zolmax.